"NATCO is the first company, after Syngenta, to launch above mentioned CTPR combination products in India. It follows on the heels of indigenously manufactured CTPR formulation 18.5% SC launched by NATCO recently under brand name NATGEN. NATCO has challenged FMC for revocation of their patents for these combination products that are marketed by Syngenta, and the case is pending before the Hon'ble High Court of Delhi", the company said in a regulatory filing on Tuesday.
At around 12:57 PM, Natco Pharma Ltd is currently trading at Rs619.30 per share up by Rs6.8 or 1.11% from its previous closing of Rs612.50 per share on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.